Nakamura, AnnaYokoyama, YokoTanaka, KazukiBenegiamo, GiorgiaHirayama, AkiyoshiZhu, QiKitamura, NahoSugizaki, TaichiMorimoto, KohkichiItoh, HiroshiFukuda, ShinjiAuwerx, JohanTsubota, KazuoWatanabe, Mitsuhiro2020-10-272020-10-272020-10-272020-09-2510.1016/j.isci.2020.101522https://infoscience.epfl.ch/handle/20.500.14299/172801WOS:000577099300006Asperuloside (ASP) is an iridoid glycoside that is extracted from Eucommia leaves. Eucommia is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.Multidisciplinary SciencesScience & Technology - Other Topicsglucagon-like peptide-1diet-induced obesityinflammationmechanismsmicepopulationresistancesuccinateprotectsextracttext::journal::journal article::research article